Job Trends
Labor Market Reports
Among those who connected salary increases to swapping out employers, 75% saw pay rise by at least 6%, and the most often cited increase was 10%, according to the just-released BioSpace salary report.
BioSpace‘s 2026 U.S. Life Sciences Salary Report delivers a comprehensive look at how salaries, bonuses and benefits evolved over the past year amid ongoing economic pressure and workforce recalibration. It uncovers not just what people are earning, but how they’re thinking about compensation, career moves and total rewards in 2026.
BioSpace data show job postings live increased quarter over quarter, while layoffs fell year over year.
Now Hiring
Looking for a biopharma job in New York? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
Looking for a clinical job? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
Last month, for the first time in nearly four years, average job postings live on BioSpace did not decline year over year. In another encouraging sign, the number of biopharmas letting employees go fell.
Career Advice
Recruiters can play a significant role in biopharma professionals getting hired, especially in an employer-driven job market. However, when working with them, candidates need to avoid making six key mistakes, from waiting too long to ask for help to prematurely contacting hiring companies.
THE LATEST
It was a moderately busy mid-summer week for clinical trial news. Here’s a look.
Master planning for the site is slated to begin in 2022 and will reportedly create one of the largest life sciences cluster in Europe.
Thermo Fisher Scientific continues to open new facilities that enable it to meet increasing manufacturing demands.
Thermo Fisher Scientific has launched a new collaborative unit that aims to standardize the metabolomics community’s efforts as it engages in more large-scale cohort studies and clinical research.
No specific financial details were disclosed other than to say the $1 billion figure was linked to various development and commercial milestones.
In its 2Q2021 Clinical Report, BioSpace highlights drugs that were greenlit for clinical studies, faced clinical and regulatory hurdles and some who saw regulatory wins.
The license and collaboration agreement center on orelabrutinib, an oral small molecule BTKi characterized by its high selectivity and the ability to cross the blood-brain barrier.
Approximately 100 preliminary reports of GBS have been identified out of 12.8 million doses of the J&J vaccine in the U.S., according to the Centers for Disease Control and Prevention.
HHS issued their announcement, saying, “Americans who have been fully vaccinated do not need a booster shot at this time.”
Sparx Therapeutics is expanding its operations into Yangzhou, China, with the imminent construction of a 1.2 million square foot facility for its commercial production.